NCT00005886已完成1 期
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 18
研究概览
简要总结
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen or LY353381 may fight breast cancer by blocking the use of estrogen.
PURPOSE: This randomized phase I trial is studying how well tamoxifen works on the biomarkers of the tumor tissue, compared with LY353381, in treating women with newly diagnosed breast cancer.
详细描述
OBJECTIVES:
- Determine whether LY353381 hydrochloride or tamoxifen administered in the interval between biopsy and re-excision alters the expression of tissue biomarkers relative to placebo controls in postmenopausal women with newly diagnosed breast cancer.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study.
- Phase I: Patients are randomized to receive either oral LY353381 hydrochloride or oral placebo daily.
Upon completion of phase I, all treatment centers begin phase II of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (18)
Loading locations...
相似试验
已完成
3 期
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast CancerBreast CancerNCT00002864NCIC Clinical Trials Group667
已完成
2 期
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast CancerStage IV Breast CancerBreast CancerNCT01124695ECOG-ACRIN Cancer Research Group124
Unknown
3 期
Adjuvant Hormone Therapy in Treating Women With Operable Breast CancerBreast CancerNCT00002460Cancer Research UK
进行中（未招募）
3 期
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerBreast CancerNCT01674140SWOG Cancer Research Network1,939
已完成
3 期
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast CancerBreast CancerNCT00002646Eastern Cooperative Oncology Group1,500